SBP-7455

SBP-7455 is a potent, high affinity and orally active dual ULK1/ULK2 autophagy inhibitor with IC50s of 13 nM and 476 nM in the ADP-Glo assays, respectively. SBP-7455 potently inhibits ULK1/2 enzymatic activity and can be used for triple-negative breast cancer (TNBC) research[1].

Product Specifications

CAS Number

[1884222-74-5]

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

Autophagy; ULK

Type

Reference compound

Related Pathways

Autophagy

Applications

COVID-19-immunoregulation

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/sbp-7455.html

Concentration

10mM

Purity

98.01

Solubility

DMSO : 125 mg/mL (ultrasonic)

Smiles

FC(C1=CN=C(NC2=CC=C(OC)C(OC)=C2)N=C1NC3CC3)(F)F

Molecular Formula

C16H17F3N4O2

Molecular Weight

354.33

Precautions

H302, H315, H319, H335

References & Citations

[1]Huiyu Ren, et al. Design, Synthesis, and Characterization of an Orally Active Dual-Specific ULK1/2 Autophagy Inhibitor that Synergizes with the PARP Inhibitor Olaparib for the Treatment of Triple-Negative Breast Cancer. J Med Chem. 2020 Dec 10;63 (23) :14609-14625